WO2012016050A3 - Chemoradiotherapy for kras-mutant colorectal cancer - Google Patents

Chemoradiotherapy for kras-mutant colorectal cancer Download PDF

Info

Publication number
WO2012016050A3
WO2012016050A3 PCT/US2011/045735 US2011045735W WO2012016050A3 WO 2012016050 A3 WO2012016050 A3 WO 2012016050A3 US 2011045735 W US2011045735 W US 2011045735W WO 2012016050 A3 WO2012016050 A3 WO 2012016050A3
Authority
WO
WIPO (PCT)
Prior art keywords
kras
chemoradiotherapy
colorectal cancer
mutant colorectal
mutant
Prior art date
Application number
PCT/US2011/045735
Other languages
French (fr)
Other versions
WO2012016050A2 (en
Inventor
Kevin Haigis
Theodore Hong
Original Assignee
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation
Publication of WO2012016050A2 publication Critical patent/WO2012016050A2/en
Publication of WO2012016050A3 publication Critical patent/WO2012016050A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

This invention relates to methods of treating KRAS-mutant cancers by administering a composition comprising Midostaurin (PKC-412), and methods for increasing the sensitivity of colorectal cancers to radiation, e.g., using Midostaurin (PKC-412) to radiosensitize colorectal cancers or cancer cells.
PCT/US2011/045735 2010-07-28 2011-07-28 Chemoradiotherapy for kras-mutant colorectal cancer WO2012016050A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36848210P 2010-07-28 2010-07-28
US61/368,482 2010-07-28

Publications (2)

Publication Number Publication Date
WO2012016050A2 WO2012016050A2 (en) 2012-02-02
WO2012016050A3 true WO2012016050A3 (en) 2012-05-24

Family

ID=45530722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/045735 WO2012016050A2 (en) 2010-07-28 2011-07-28 Chemoradiotherapy for kras-mutant colorectal cancer

Country Status (1)

Country Link
WO (1) WO2012016050A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015041837A1 (en) 2013-09-19 2015-03-26 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
JP2015096049A (en) * 2013-11-15 2015-05-21 凸版印刷株式会社 Method for predicting long-term success of vegf inhibitor
AU2016243512A1 (en) * 2015-03-27 2017-11-09 The Research Foundation For The State University Of New York Methods and materials for treating cancer
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325104A (en) * 1963-07-15 1967-06-13 Hartford Machine Screw Fuel injection nozzle
US6543421B2 (en) * 2000-03-21 2003-04-08 Siemens Automotive Corporation Fuel injector assembly for mounting a fuel injector to a fuel rail and permitting alignment of the fuel injector

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325104A (en) * 1963-07-15 1967-06-13 Hartford Machine Screw Fuel injection nozzle
US6543421B2 (en) * 2000-03-21 2003-04-08 Siemens Automotive Corporation Fuel injector assembly for mounting a fuel injector to a fuel rail and permitting alignment of the fuel injector

Also Published As

Publication number Publication date
WO2012016050A2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2014018563A3 (en) Methods for the treatment of cancer
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2012177844A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
WO2012048099A3 (en) Nanoparticle-loaded cells
MX370721B (en) Novel compounds and compositions for targeting cancer stem cells.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
WO2010003520A3 (en) Anti-tumor immunotherapy
MY184101A (en) Indoles
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014116833A3 (en) Compositions and methods for detecting neoplasia
MX2013010475A (en) Yeast-brachyury immunotherapeutic compositions.
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
PH12015501088A1 (en) Dimeric compounds
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
EP2355843B8 (en) Vaccine for the prevention of breast cancer recurrence
WO2012024350A3 (en) Anti-cancer adenoviruses
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
WO2011100642A3 (en) Method for treating hematological cancers
WO2012016050A3 (en) Chemoradiotherapy for kras-mutant colorectal cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813188

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11813188

Country of ref document: EP

Kind code of ref document: A2